Hyperglycemia triggers HIPK2 protein degradation

S. Baldari, A. Garufi, M. Granato, L. Cuomo, G. Pistritto, M. Cirone, G. D'Orazi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Homeodomain interacting protein kinase-2 (HIPK2) is an evolutionary conserved kinase that modulates several key molecular pathways to restrain tumor growth and induce p53-depending apoptotic cell-death in response to anticancer therapies. HIPK2 silencing in cancer cells leads to chemoresistance and cancer progression, in part due to p53 inhibition. Recently, hyperglycemia has been shown to reduce p53 phosphorylation at serine 46 (Ser46), the target residue of HIPK2, thus impairing p53 apoptotic function. Here we asked whether hyperglycemia could, upstream of p53, target HIPK2. We focused on the effect of high glucose (HG) on HIPK2 protein stability and the underlying mechanisms. We found that HG reduced HIPK2 protein levels, therefore impairing HIPK2-induced p53 apoptotic activity. HG-triggered HIPK2 protein downregulation was rescued by both proteasome inhibitor MG132 and by protein phosphatase inhibitors Calyculin A (CL-A) and Okadaic Acid (OA). Looking for the phosphatase involved, we found that protein phosphatase 2A (PP2A) induced HIPK2 degradation, as evidenced by directly activating PP2A with FTY720 or by silencing PP2A with siRNA in HG condition. The effect of PP2A on HIPK2 protein degradation could be in part due to hypoxia-inducible factor-1 (HIF-1) activity which has been previously shown to induce HIPK2 proteasomal degradation through several ubiquitin ligases. Validation analysed performed with HIF-1alpha dominant negative or with silencing of Siah2 ubiquitin ligase clearly showed rescue of HG-induced HIPK2 degradation. These findings demonstrate how hyperglycemia, through a complex protein cascade, induced HIPK2 downregulation and consequently impaired p53 apoptotic activity, revealing a novel link between diabetes/obesity and tumor resistance to therapies.
Original languageEnglish
Pages (from-to)1190-1203
Number of pages14
JournalOncotarget
Volume8
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Homeodomain Proteins
Hyperglycemia
Protein Kinases
Proteolysis
Protein Phosphatase 2
Glucose
Ligases
Ubiquitin
Neoplasms
Down-Regulation
Hypoxia-Inducible Factor 1
Okadaic Acid
Proteins
Proteasome Inhibitors
Protein Stability
Phosphoprotein Phosphatases
Phosphoric Monoester Hydrolases
Serine
Small Interfering RNA

Keywords

  • HIPK2
  • PP2A
  • cancer
  • hyperglycemia
  • p53

Cite this

Baldari, S., Garufi, A., Granato, M., Cuomo, L., Pistritto, G., Cirone, M., & D'Orazi, G. (2017). Hyperglycemia triggers HIPK2 protein degradation. Oncotarget, 8(1), 1190-1203. https://doi.org/10.18632/oncotarget.13595 [doi]

Hyperglycemia triggers HIPK2 protein degradation. / Baldari, S.; Garufi, A.; Granato, M.; Cuomo, L.; Pistritto, G.; Cirone, M.; D'Orazi, G.

In: Oncotarget, Vol. 8, No. 1, 2017, p. 1190-1203.

Research output: Contribution to journalArticle

Baldari, S, Garufi, A, Granato, M, Cuomo, L, Pistritto, G, Cirone, M & D'Orazi, G 2017, 'Hyperglycemia triggers HIPK2 protein degradation', Oncotarget, vol. 8, no. 1, pp. 1190-1203. https://doi.org/10.18632/oncotarget.13595 [doi]
Baldari S, Garufi A, Granato M, Cuomo L, Pistritto G, Cirone M et al. Hyperglycemia triggers HIPK2 protein degradation. Oncotarget. 2017;8(1):1190-1203. https://doi.org/10.18632/oncotarget.13595 [doi]
Baldari, S. ; Garufi, A. ; Granato, M. ; Cuomo, L. ; Pistritto, G. ; Cirone, M. ; D'Orazi, G. / Hyperglycemia triggers HIPK2 protein degradation. In: Oncotarget. 2017 ; Vol. 8, No. 1. pp. 1190-1203.
@article{e58b1789a6b04e33aeedd2ad69faf9b3,
title = "Hyperglycemia triggers HIPK2 protein degradation",
abstract = "Homeodomain interacting protein kinase-2 (HIPK2) is an evolutionary conserved kinase that modulates several key molecular pathways to restrain tumor growth and induce p53-depending apoptotic cell-death in response to anticancer therapies. HIPK2 silencing in cancer cells leads to chemoresistance and cancer progression, in part due to p53 inhibition. Recently, hyperglycemia has been shown to reduce p53 phosphorylation at serine 46 (Ser46), the target residue of HIPK2, thus impairing p53 apoptotic function. Here we asked whether hyperglycemia could, upstream of p53, target HIPK2. We focused on the effect of high glucose (HG) on HIPK2 protein stability and the underlying mechanisms. We found that HG reduced HIPK2 protein levels, therefore impairing HIPK2-induced p53 apoptotic activity. HG-triggered HIPK2 protein downregulation was rescued by both proteasome inhibitor MG132 and by protein phosphatase inhibitors Calyculin A (CL-A) and Okadaic Acid (OA). Looking for the phosphatase involved, we found that protein phosphatase 2A (PP2A) induced HIPK2 degradation, as evidenced by directly activating PP2A with FTY720 or by silencing PP2A with siRNA in HG condition. The effect of PP2A on HIPK2 protein degradation could be in part due to hypoxia-inducible factor-1 (HIF-1) activity which has been previously shown to induce HIPK2 proteasomal degradation through several ubiquitin ligases. Validation analysed performed with HIF-1alpha dominant negative or with silencing of Siah2 ubiquitin ligase clearly showed rescue of HG-induced HIPK2 degradation. These findings demonstrate how hyperglycemia, through a complex protein cascade, induced HIPK2 downregulation and consequently impaired p53 apoptotic activity, revealing a novel link between diabetes/obesity and tumor resistance to therapies.",
keywords = "HIPK2, PP2A, cancer, hyperglycemia, p53",
author = "S. Baldari and A. Garufi and M. Granato and L. Cuomo and G. Pistritto and M. Cirone and G. D'Orazi",
note = "LR: 20161203; JID: 101532965; OTO: NOTNLM; 2016/08/04 [received]; 2016/11/08 [accepted]; aheadofprint",
year = "2017",
doi = "10.18632/oncotarget.13595 [doi]",
language = "English",
volume = "8",
pages = "1190--1203",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - Hyperglycemia triggers HIPK2 protein degradation

AU - Baldari, S.

AU - Garufi, A.

AU - Granato, M.

AU - Cuomo, L.

AU - Pistritto, G.

AU - Cirone, M.

AU - D'Orazi, G.

N1 - LR: 20161203; JID: 101532965; OTO: NOTNLM; 2016/08/04 [received]; 2016/11/08 [accepted]; aheadofprint

PY - 2017

Y1 - 2017

N2 - Homeodomain interacting protein kinase-2 (HIPK2) is an evolutionary conserved kinase that modulates several key molecular pathways to restrain tumor growth and induce p53-depending apoptotic cell-death in response to anticancer therapies. HIPK2 silencing in cancer cells leads to chemoresistance and cancer progression, in part due to p53 inhibition. Recently, hyperglycemia has been shown to reduce p53 phosphorylation at serine 46 (Ser46), the target residue of HIPK2, thus impairing p53 apoptotic function. Here we asked whether hyperglycemia could, upstream of p53, target HIPK2. We focused on the effect of high glucose (HG) on HIPK2 protein stability and the underlying mechanisms. We found that HG reduced HIPK2 protein levels, therefore impairing HIPK2-induced p53 apoptotic activity. HG-triggered HIPK2 protein downregulation was rescued by both proteasome inhibitor MG132 and by protein phosphatase inhibitors Calyculin A (CL-A) and Okadaic Acid (OA). Looking for the phosphatase involved, we found that protein phosphatase 2A (PP2A) induced HIPK2 degradation, as evidenced by directly activating PP2A with FTY720 or by silencing PP2A with siRNA in HG condition. The effect of PP2A on HIPK2 protein degradation could be in part due to hypoxia-inducible factor-1 (HIF-1) activity which has been previously shown to induce HIPK2 proteasomal degradation through several ubiquitin ligases. Validation analysed performed with HIF-1alpha dominant negative or with silencing of Siah2 ubiquitin ligase clearly showed rescue of HG-induced HIPK2 degradation. These findings demonstrate how hyperglycemia, through a complex protein cascade, induced HIPK2 downregulation and consequently impaired p53 apoptotic activity, revealing a novel link between diabetes/obesity and tumor resistance to therapies.

AB - Homeodomain interacting protein kinase-2 (HIPK2) is an evolutionary conserved kinase that modulates several key molecular pathways to restrain tumor growth and induce p53-depending apoptotic cell-death in response to anticancer therapies. HIPK2 silencing in cancer cells leads to chemoresistance and cancer progression, in part due to p53 inhibition. Recently, hyperglycemia has been shown to reduce p53 phosphorylation at serine 46 (Ser46), the target residue of HIPK2, thus impairing p53 apoptotic function. Here we asked whether hyperglycemia could, upstream of p53, target HIPK2. We focused on the effect of high glucose (HG) on HIPK2 protein stability and the underlying mechanisms. We found that HG reduced HIPK2 protein levels, therefore impairing HIPK2-induced p53 apoptotic activity. HG-triggered HIPK2 protein downregulation was rescued by both proteasome inhibitor MG132 and by protein phosphatase inhibitors Calyculin A (CL-A) and Okadaic Acid (OA). Looking for the phosphatase involved, we found that protein phosphatase 2A (PP2A) induced HIPK2 degradation, as evidenced by directly activating PP2A with FTY720 or by silencing PP2A with siRNA in HG condition. The effect of PP2A on HIPK2 protein degradation could be in part due to hypoxia-inducible factor-1 (HIF-1) activity which has been previously shown to induce HIPK2 proteasomal degradation through several ubiquitin ligases. Validation analysed performed with HIF-1alpha dominant negative or with silencing of Siah2 ubiquitin ligase clearly showed rescue of HG-induced HIPK2 degradation. These findings demonstrate how hyperglycemia, through a complex protein cascade, induced HIPK2 downregulation and consequently impaired p53 apoptotic activity, revealing a novel link between diabetes/obesity and tumor resistance to therapies.

KW - HIPK2

KW - PP2A

KW - cancer

KW - hyperglycemia

KW - p53

U2 - 10.18632/oncotarget.13595 [doi]

DO - 10.18632/oncotarget.13595 [doi]

M3 - Article

VL - 8

SP - 1190

EP - 1203

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -